A Randomized, Double-Blind, Placebo Controlled Multi-Center and Parallel Group Study of the Safety, Tolerability and Efficacy of YM150 in Combination With Standard Treatment in Secondary Prevention of Ischemic Vascular Events in Subjects With Acute Coronary Syndromes.

Trial Profile

A Randomized, Double-Blind, Placebo Controlled Multi-Center and Parallel Group Study of the Safety, Tolerability and Efficacy of YM150 in Combination With Standard Treatment in Secondary Prevention of Ischemic Vascular Events in Subjects With Acute Coronary Syndromes.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Darexaban (Primary)
  • Indications Acute coronary syndromes; Embolism and thrombosis
  • Focus Adverse reactions; Pharmacogenomic
  • Acronyms RUBY-1
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 30 Aug 2011 Results presented at the ESC Congress 2011: Annual Congress of the European Society of Cardiology.
    • 30 Aug 2011 Actual patient number reported at the ESC Congress 2011: Annual Congress of the European Society of Cardiology.
    • 07 Feb 2011 Actual initiation date changed from 29 Sep 2009 to 1 Sep 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top